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The computer software used for genomic analysis has
become a crucial component of the infrastructure for
life sciences. However, genomic software is still
typically developed in an ad hoc manner, with
inadequate funding, and by academic researchers not
trained in software development, at substantial costs
to the research community. I examine the roots of the
incongruity between the importance of and the
degree of investment in genomic software, and I
suggest several potential remedies for current
problems. As genomics continues to grow, new
strategies for funding and developing the software
that powers the field will become increasingly
essential.
A traveler in late-eighteenth-century England who passed
through the town of Slough—located just west of London
and not far from present-day Heathrow Airport—might
have come upon a massive 40-ft-long telescope, sus-
pended in a wooden frame more than 50 ft tall (Fig. 1a).
The telescope was located at the home of William
Herschel and his sister Caroline, two of the greatest
astronomers of their day. It was the largest telescope
in the world until it was dismantled in 1839. Weigh-
ing over 1000 lbs., the “40-ft telescope”, as it was
known, was sufficiently impressive to the general pub-
lic to emerge as a regional tourist attraction. Its auda-
cious scale inspired prominent thinkers and writers of
the time, including Erasmus Darwin and William
Blake [1, 5].
The 40-ft telescope took 5 years to build and was paid
for by a grant of £4000 from King George III, who was
strongly committed to scientific research throughout his
reign. This grant represented a substantial sum at the
time, roughly equivalent to £600,000 (about US$800,000)© The Author(s). 2019 Open Access This artic
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Simons Center for Quantitative Biology, Cold Spring Harbor Laboratory, Cold
Spring Harbor, NY 11724, USAin 2019 [6]. There were no formal mechanisms at the time
for grant applications for scientific research. Instead,
William Herschel simply approached the King directly
with a request for royal patronage. The 40-ft tele-
scope is one of the earliest examples of government
investment in the infrastructure for scientific research,
to enable a project that simply would not have been
possible with private funds alone.
The model of government investment in scientific in-
frastructure became increasingly well-established
throughout the 19th and 20th centuries, culminating in
the “Big Science” of the World War II and Post-War
eras. Science in modern times has been dominated, in
many ways, by these massive public investments. Prom-
inent examples include the Manhattan project (equiva-
lent to $22 billion in 2016 [7, 8]), the Apollo program
(equivalent to $107 billion [9]), the Space Shuttle pro-
gram (equivalent to $219 billion [10]), the Large Hadron
Collider (equivalent $4.8 billion [11]) and, more pertin-
ent to this article, the Human Genome Project (equiva-
lent to $5.0 billion [12]; Fig. 1b).
Indeed, we now live in a world where much of the day-
to-day work in science depends on a publicly funded in-
frastructure. In particular, many working in genomics rely
heavily on data sets such as those generated by the
ENCODE, Roadmap Epigenomics, 1000 Genomes,
Genotype-Tissue Expression (GTEx), The Cancer Genome
Atlas (TCGA), Genetic European Variation in Disease
(GEUVADIS), and most recently, Human Cell Atlas pro-
jects. We store and search sequence data using GenBank,
EMBL-Bank, DDBJ, UniProt, and Pfam, examine three-
dimensional protein structures in PDB or EMDB, scour
the literature using PubMed, and view genomic annota-
tions using the UCSC Genome Browser and Ensembl
Browser. All these resources have been maintained for de-
cades either directly by government agencies or through
long-term public funding to universities and research
institutes.
The computer software on which millions of scientists
rely for genomic analysis is no less an essential part of thele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
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Fig. 1 a William and Caroline Herschel’s 40-foot telescope in Slough, England, 1789 [1]. b Two of the teams of scientists that contributed to the
Human Genome Project: (top) Sanger Center, Hinxton, UK [2]; (bottom) Washington University Genome Sequencing Center, St. Louis, USA, both
circa 2000. c Some relics of the pre-Internet world: (clockwise from top left) the author learning to program in BASIC on a Commodore 64 in a
cold upstate New York basement, 1983 (credit: Virginia Siepel), as one of the millions of children who were introduced to home computers
during the 1980s and 1990s, some of whom would go on to write much of the software that powers genomics today; floppy disk for PAUP
version 3.1.1,©1993; Sun Microsystems SPARCstation 1 with Mosaic web browser faintly visible on screen, 1994 [3]; screen shot from the MASE
alignment program [4]. d Prof. David Haussler of UC Santa Cruz with the original Dell computer cluster that his team used to assemble the
human genome, 2000. Photo (c) UC Santa Cruz, used with permission
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sets or public databases, yet the model for funding and de-
veloping computer software differs substantially. Most
widely used genomic software is developed by independ-
ent investigators working in academic or not-for-profit in-
stitutions with support from government grants. This
software is generally freely available to the community,
typically with no subscription or licensing fees and nonre-
strictive terms of use. At the same time, it is often mea-
gerly funded, unreliable, hard-to-use, poorly documented,
and/or poorly supported. How did we, as a community,arrive at this odd situation? Why is scientific software sup-
ported differently from other forms of scientific infrastruc-
ture? Why are adequate funds not set aside for this
important work?
In this article, I offer my perspective on the unique
problem of funding and developing software for genom-
ics, based on my 25 years in the field—as a developer
and user of software, a professional programmer and
principal investigator, an applicant for and reviewer of
grant proposals, and an employee of government, uni-
versity, and private research institutions. I first examine
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how the field has come to be the way it is. Overall, I
argue that, despite some important strengths of our
current model for software development, we as a com-
munity have “painted ourselves into a corner” in terms
of developing robust, well-engineered software and are
paying for it; we are, in a sense, addicted to free soft-
ware. Finally, I suggest some possible remedies that at-
tempt to strike a balance between addressing important
deficiencies in the current model and maintaining its
core strengths. My discussion of these topics necessarily
have a US bias, but I believe that many of my points are
internationally valid. Also, although this article focuses
on genomics, similar trends occur in other areas of com-
putational biology, such as structural biology and prote-
omics, as well as in some other areas of scientific
software development.
Software for genomics is critical to the research
infrastructure for the life sciences
During the past 25 years, genomic software development
has grown from an obscure cottage industry to an essen-
tial part of the infrastructure of biological research. Re-
searchers across the globe rely on computational tools
for read mapping, genome assembly, multiple alignment,
phylogenetics, population genomics, and visualization of
genomic data, among many other applications. Import-
antly, these tools are no longer used only by genomic
specialists, but across all the life sciences, including dis-
parate fields such as ecology and evolution, molecular
and cell biology, clinical genetics, plant breeding, bio-
physics, and bioengineering. To take one measure of im-
pact, the papers describing popular genomic software
tools are among the most highly cited publications in
the scientific literature [13, 14]. For example, Table 1
lists 66 well-known genomic software tools, from various
application areas, each of which has been cited at least
2000 times and, in some cases, many tens of thousands
of times (for reference, only about 1 in 100,000 scientific
papers is cited more than 2000 times, based on estimates
from Open Academic Graph [152], a bibliographic data-
base of ~ 700 million publications (analysis restricted to
biology-related publications)). Indeed, nowadays it is
rare to encounter a scientific publication that makes use
of DNA, RNA, or protein sequences but does not refer-
ence one or more tools of this type.
Because the reach of genomics software is so vast, it is
difficult to measure its economic importance. Neverthe-
less, the US government spends at least ~ $16 billion per
year on basic research in the life sciences (spending on
research and development by the US Federal govern-
ment was estimated at $118 billion in 2017, of which
$32 billion was dedicated to basic research. The life sci-
ences account for approximately half of all spending,suggesting approximately $16 billion is spent on basic
life sciences research [153]). If even 10% of these funds
are devoted to projects that rely in part on genomics
and genomic software, which seems plausible, then this
software would be instrumental in supporting more than
a billion dollars per year in research. Furthermore, total
R&D expenditures in the US are estimated at about four
times those of the federal government, and scaling up to
worldwide R&D expenditures requires about another
factor of three. (Total R&D expenditures in the US, in-
cluding those in the private sector and at other govern-
mental levels, are estimated at about $500 billion
annually. The US leads the world in spending on sci-
ence, but China is not far behind, and several other
countries—including Japan, Germany, South Korea,
France, and the UK—also account for substantial
amounts. Together, the top ten countries spend about
$1.5 trillion per year on R&D [154]). Therefore, a rough
calculation suggests that the worldwide research that de-
pends, at least in part, on genomic software is likely to
cost tens of billions of dollars annually.
Software for genomics lacks a sustainable model
for development and maintenance
Despite the overwhelming importance of genomic soft-
ware, there is broad agreement among practitioners that
the current model for its development has serious flaws.
As noted above, most genomic software is developed by
academic groups and funded by government grants, yet
there are relatively few dedicated granting opportunities
for genomic software development, and those that exist
have relatively low levels of funding (see Table 2 for ex-
amples of recent and current funding programs). More
typically, software development efforts in genomics have
to be cloaked as research, for example, by describing the
development of a software tool as a single aim or sub-
aim of a research grant that is ostensibly focused on bio-
logical discovery. Additional funding for computational
genomics has been made available through consortium
projects, community databases, and browsers (for ex-
ample, through U24, U41, and U54 opportunities at the
US National Institutes of Health (NIH)), but the scope
of this work is often quite constrained. Despite that the
most widely used tools have been developed by individ-
ual laboratories pursuing investigator-initiated work
(Table 1), the funding for projects of this kind remains
limited.
It is particularly difficult for academic researchers to
obtain funding to extend, refine, or support software
tools that have already proven to be widely useful to the
community—for example, to improve performance, us-
ability, robustness, or documentation, or to provide sup-
port for bug fixes and user questions. Except in a few
special cases (for example, the Continued Development
Table 1 Highly cited genomic software tools
Program name Yeara Primary institution(s)b Primary funding source(s)c Refs.d Citationse
Homology searching and alignment
FASTA 1988 U. Virginia, NIH NA [15] 13,496
CLUSTAL 1988 Trinity College, Dublin; EMBL, Heidelberg;
EBI
European Community Biotechnology Action
Programme
[16–20] 94,789
BLAST 1990 NCBI NIH [21] 75,328
PSI-BLAST 1997 NCBI NIH [22] 69,604
HMMer 1998 Washington U., St. Louis NIH, HHMI [23–25] 8,836
T-Coffee 2000 Nat. Inst. Med. Res., London Swiss Nat’l Science Fnd. [26] 6,247
BLAT 2002 UC Santa Cruz NIH, HHMI [27] 6,911
MUSCLE 2004 drive5.com NA [28] 24,261
MAFFT 2013 Kyoto U. Ministry of Education, Culture, Sports, and
Technology of Japan
[29–33] 21,486
Phylogenetic modeling and tree inference
PHYLIP 1980 U. Washington NIH, NSF [34] 21,851
MacClade 1986 Sinauer Assoc. (Commercial) [35] 10,255
PAUP 1989 Illinois Nat. Hist. Survey, Sinauer Assoc. (Commercial) [4] 62,807
PAML 1993 UC Berkeley, Univ. College London NSF of China, NIH, NSF [36, 37] 11,375
MEGA 1993 Penn. State U., Arizona State U. NIH, NSF, Burroughs-Wellcome [38–42] 119,268
Mr. Bayes 2001 U. Rochester, Uppsala U. NSF [43–45] 52,742
Mesquite 2001 U. Arizona, U. British Columbia Packard, NSF [46] 7,693
PhyML 2003 CNRS, Montpellier Montpellier Genopole, InterEPST Bioinformatics
Program
[47–50] 24,614
PHAST 2004 UC Santa Cruz, Cornell NSF, Packard, NIH [51–55] 4,690
RAxML 2004 Technical U. Munich Heidelberg Institute for Theoretical Studies [56–59] 27,550
HyPhy 2005 UC San Diego, NC State NA [60] 2,159
BEAST 2007 U. Auckland, U. Edinburgh Wellcome Trust, Royal Society [61, 62] 12,027
FastTree/FastTree2 2009 Lawrence Berkeley Nat’l Lab, UC Berkeley DOE, GTL Program [63, 64] 5,308
Gene prediction, motif finding, and RNA folding
MEME 1994 UC San Diego NIH, NSF [65–69] 11,790
Genscan 1997 Stanford NIH, NSF [70] 4,061
tRNAscan-SE 1997 Washington U., St. Louis NA [71] 7,559
Vienna package 2003 Institute for Theoretical Chemistry, Austria Austrian Science Fund [72–74] 4,781
Visualization
Jalview 1996 EBI, Sanger, Oxford BBSRC [75, 76] 5,895
TreeView 1998 Stanford NIH [77] 17,796
UCSC Genome Browser 2000 UC Santa Cruz NIH, DOE, HHMI [78–82] 11,365
ENSEMBL Browser 2000 EBI, Sanger Wellcome Trust, NIH, EMBL [83–87] 5,235
Cytoscape 2003 Inst. Systems Biology, Whitehead Inst.,
UC San Diego
Pfizer, NIH, NSF [88–90] 17,862
IGV 2011 Broad NIH [91] 4,678
Statistical and population genomics
STRUCTURE 2000 Oxford NIH, Burroughs-Wellcome, BBRC [92, 93] 30,948
PHASE/fastPHASE 2001 Oxford, U. Washington Wellcome Trust, BBSRC, Engineering and
Physical Sciences Research Council
[94–96] 10,073
ms 2002 U. Chicago NA [97] 2,119
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Table 1 Highly cited genomic software tools (Continued)
Program name Yeara Primary institution(s)b Primary funding source(s)c Refs.d Citationse
PolyPhen 2002 EMBL, Max Delbrück Center for Mol. Med.,




SIFT 2003 Fred Hutchinson Cancer Res. Ctr. NIH [101,
102]
7,024
EIGENSTRAT 2006 Harvard, Broad Millenium Pharmaceuticals, Burroughs
Wellcome
[103] 6,812
PLINK 2007 MGH, Broad, U. Hong Kong NIH [104,
105]
17,938
TASSEL 2007 USDA-ARS, Cornell USDA-ARS, NSF [106] 2,609





IMPUTE/IMPUTE2 2007 Oxford Wellcome Trust, NIH [109,
110]
4,930
VCFtools 2011 Sanger Medical Research Council, British Heart
Foundation, Wellcome Trust, NIH
[111] 3,133
CADD 2014 U. Washington NIH [112] 2,353
Functional genomics, annotations, and transcriptomics
Gene Ontology 2000 UC Berkeley, Stanford NIH, Astra Zeneca [113] 22,898
GSEA 2005 Broad NA [114] 16,135
MACS/MACS2 2008 Dana-Farber, Harvard NIH [115,
116]
5,965
TopHat/Cufflinks 2009 U. Maryland NIH, NSF [117–
120]
28,242
ChromHMM 2010 MIT, Broad NSF, NIH [121–
123]
3,977
BEDtools 2010 U. Virginia NIH, Burroughs-Wellcome [124,
125]
7,137
edgeR 2010 Garavan Inst. Med. Res., Walter & Eliza Hall
Inst. Med. Res., Australia
NHMRC [126] 9,992
Trinity 2011 MIT, Broad NIH, US-Israel Binational Science Foundation [127] 7,178
DEseq/DEseq2 2012 EMBL NA [128,
129]
16,355
Assembly, read mapping, and base/variant calling
Staden package 1977 LMB NA [130–
134]
5,029
Phred 1993 Washington U., St. Louis, U. Washington NIH [135,
136]
12,172
MAQ 2008 Sanger Wellcome Trust [137] 2,777
ALLPATHS/ALLPATHS-
LG
2008 Broad, MGH NIH [138,
139]
2,079
Velvet 2008 EBI EMBL [140] 7,635
Bowtie/Bowtie2 2009 U. Maryland NIH [141,
142]
26,607
BWT 2009 Sanger Wellcome Trust [143] 17,546
SOAP2 2009 Beijing Genomics Inst., U. Southern
Denmark
National Natural Science Foundation of China,
Danish Natural Science Research Council
[144] 2,818
SAMtools 2009 Sanger Wellcome Trust, NIH [145] 17,811
ABySS 2009 Genome Sciences Centre, Vancouver, BC Genome Canada, Genome British Columbia,
British Columbia Cancer Foundation
[146] 2,761
GATK 2010 Broad, MGH NIH [147] 9,291
SOAPdenovo/ 2010 Beijing Genomics Inst. Chinese Academy of Science, National Natural [148, 4,295
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Table 1 Highly cited genomic software tools (Continued)
Program name Yeara Primary institution(s)b Primary funding source(s)c Refs.d Citationse
SOAPdenovo2 Science Foundation of China 149]
STAR 2013 CSHL NIH [150,
151]
6,013
a Approximate first year available, or year of first publication if unknown
bInstitutions most central in supporting project, or affiliations of first and last authors of first publication if unknown. Broad Eli & Edythe Broad Institute of MIT &
Harvard, USA; CNRS Centre National de la Recherche Scientifique, France; CSHL Cold Spring Harbor Laboratory, USA; EBI European Bioinformatics Institute; EMBL
European Molecular Biology Laboratory; HSPH Harvard School of Public Health, USA; LMB Laboratory of Molecular Biology, UK; MGH Massachusetts General
Hospital, USA; Sanger Wellcome Trust Sanger Institute, UK
c BBSRC Biotechnology & Biological Sciences Research Council, UK; HHMI Howard Hughes Medical Institute, US; NA not applicable; NCBI National Center for
Biotechnology Information, US; NHMRC The National Health & Medical Research Council, Australia; NIH National Institutes of Health, US; NSF National Science
Foundation, US; USDA-ARS United States Department of Agriculture - Agriculture Research Service; Packard David & Lucile Packard Foundation
d Most highly cited associated publications (at most five)
e Total number of citations, obtained from Google Scholar on Feb. 22, 2019
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fered by the NIH; Table 2), grant review panels tend to
consider projects of this kind to be insufficiently novel
to be supported either by dedicated research grants or as
components of grants focused on biological discovery.
One might expect that this type of engineering-focused
work would more naturally be provided by the private
sector, as with laboratory equipment or reagents but,
despite decades of anticipation, there is still no thriving
commercial market for genomics software. It is true that
biotech and pharmaceutical companies often have their
own in-house software development groups, but there
seems to be, at best, weak demand for these products in
the larger research community. Moreover, current trends
point in the wrong direction, with several relevant
grant opportunities having recently been discontinued
(Table 2) and little indication of the emergence of a
robust commercial market.
In part owing to these financial limitations, it is diffi-
cult to recruit and retain professional software devel-
opers in academic settings. Perhaps the most severe
challenge is that the salary structures and budget models
for academic institutions are generally not set up to ac-
commodate six-figure salaries for workers who are not
principal investigators or high-level administrators. As a
result, software engineers typically accept a substantial
salary reduction—of sometimes 50% or more—for the
“privilege” of working in scientific research, as opposed
to working for an established or start-up high-tech com-
pany. (The average salary for an entry-level software en-
gineer in San Francisco, CA is about $110,000 [155].)
Furthermore, academic research institutions often do
not provide attractive career paths for software devel-
opers, offering them, for example, limited options for
career advancement, few awards or accolades, and at
most small communities of career-matched peers.
Instead, software development is often done by gradu-
ate students and postdoctoral researchers who have
other priorities and, in many cases, no direct training in
the area. Some principal investigators also devoteconsiderable amounts of their own time to software de-
velopment, but these activities must be balanced against
many other responsibilities, including teaching, mentor-
ing, writing scientific papers, and raising funds. There-
fore, genomic software development tends to be done
on a low budget, with many short-cuts to software en-
gineering best practices.
Software packages developed in this way tend to be
sparsely documented, difficult to install and use, re-
stricted to specific platforms, and unreliable. In addition,
the support and maintenance of released packages tends
to be inconsistent, typically relying on email contact
with busy and distracted principal investigators or
trainees, and often effectively ending when a key student
or postdoctoral researcher changes jobs. All these factors
combine to produce a great deal of wasted time and
frustration for the users of genomic software. They also
contribute to severe challenges in reproducibility in gen-
omic analysis. Indeed, a recent review of nearly 25,000
“omics” software resources published from 2000 to 2017
found that 26% were no longer accessible through URLs
published in the corresponding papers [156]. Among ac-
cessible tools, 28% could not be installed, and another
21% were deemed “difficult to install.” Together, it ap-
pears that, as a field, we are on an unsustainable path
for genomic software development. We do not set aside
adequate funding for it, we fail to encourage and enforce
good engineering practices, we have inadequate struc-
tures for recruiting and retaining the workers we need,
and we continually pay a high price in reliability, usabil-
ity, and performance.
Other aspects of the infrastructure for genomics
have alternative funding models
Interestingly, other aspects of the infrastructure for gen-
omics have followed rather different models. DNA se-
quencing instruments, for example, have for decades
been primarily developed and marketed by companies
such as Applied Biosystems (now part of Thermo Fisher
Scientific), Illumina, Oxford Nanopore Technologies
Table 2 Grant opportunities for genomic software development
Title Source Country Last call Funding rate
Bioinformatics and Computational Biology Genome Canada Canada 2017 CAD$12M
Cyberinfrastructure Initiative Canada Foundation for Innovation Canada 2017 ~ CAD$10 M
Research Software Program CANARIE Canada Open CAD$4.5 M
ELIXIR Tools Platform ELIXIR (Europe) Open NA
Call for Challenges and Unlocking of Technological
and Scientific Barriers
Institut Français de Bioinformatique
(IFB)
France Open NA
Accelerating Scientific Discovery Netherlands eScience Netherlands 2018 ~€1 M
Bioinformatics and Biological Resources Fund BBSRC UK 2017 Up to £6 M
Transformative Research Technologies BBSRC, EPSRC, MRC UK 2017 Up to £3.5 M
Collaborative Computational Tools for the Human
Cell Atlas
Chan-Zuckerberg Initiative USA 2017 $15 M
Continued Development and Maintenance of Software NIH USA 2014 NA
Cyberinfrastructure for Sustained Scientific Innovation NSF (spans Directorates) USA Open $46.5 M
Data-Driven Discovery Investigator Competition Gordon and Betty Moore Foundation USA 2014 $22.5 M
Extended Development, Hardening & Dissemination
of Technologies in Biomedical Computing, Informatics
& Big Data Science
NIH USA 2014 NA
Informatics Technology for Cancer Research NCI/NIH USA 2018 NA
Infrastructure Capacity for Biology NSF Division of Biological Infrastructure
(DBI)
USA Open $40 M
Innovation in Cancer Informatics Fund for Innovation in Cancer
Informatics
USA Open ~ $1 M
Investigator Initiated Research in Computational Genomics
and Data Science
NHGRI/NIH USA Open NA
BBSRC-NSF/BIO Lead Agency Opportunity in Bioinformatics
and Synthetic Biology
NSF Directorate for Biological Sciences
(NSF/BIO), BBSRC
USA/UK 2018 NA
BBSRC Biotechnology and Biological Sciences Research Council, UK; EPSRC Engineering and Physical Sciences Research Council, UK; MRC Medical Research Council,
UK; NA not applicable; NCI National Cancer Institute, US; NHGRI National Human Genome Research Institute, US; NIH National Institutes of Health, US; NSF National
Science Foundation, US
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Biosciences of California. The microarray market was
(and remains) similarly commercial, at least following an
initial experimental phase, with companies such as
Affymetrix (also now part of Thermo Fisher Scientific)
and Agilent Technologies dominant. Laboratory equip-
ment is provided by companies such as PerkinElmer,
Bio-Rad Laboratories, and Becton Dickinson (BD), and
computer hardware is provided by Intel, AMD, Apple,
Microsoft, Dell, Samsung, Acer, Hewlett-Packard, and
many others. These are areas of technology development
with substantial “bricks and mortar” needs, including
major manufacturing operations, and they address suffi-
ciently large markets with sufficiently high profit mar-
gins such that free enterprise is able to meet the needs
of scientific research. Despite the general feeling of cor-
porate skepticism among academic scientists, these com-
panies are viewed, by and large, as positive forces for
innovation that are complementary to academic science.
By contrast, large, widely used public databases, such
as GenBank, EMBL-Bank, and PDB, tend to be directlysupported by government agencies or by long-standing
government grants. Even smaller database projects lo-
cated at universities or private research institutes, such
as FlyBase, the Saccharomyces Genome Database (SGD),
or the Mouse Genome Database (MGD), tend to have
substantial, repeatedly renewed government grants.
Thus, it seems that there is an implicit understanding in
genomics that the management of large public data sets
should be centralized and government-supported, while
the hardware and instruments used for generating and
analyzing data should be provided by the free market.
Why is software different from both?
Roots: dawn of the modern era for computational
genomics
When I started working in computational genomics in
1994, as a research assistant at Los Alamos National La-
boratory (LANL), the software landscape in the field had
a distinctly different feel. Free software was much less
plentiful and co-existed symbiotically with widely used
commercial products. In the HIV Sequence Database
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copies of MacClade [35], PAUP [4], and the Genetics
Computer Group’s (GCG) Wisconsin Package, along-
side free software such as MASE [4], BLAST [21],
and PHYLIP [34] (Fig. 1c). In addition, “serious” com-
putational scientists at the time generally used expensive
proprietary UNIX systems rather than commodity hard-
ware. Linux was still a hobbyist’s operating system and
largely invisible in research settings. Similarly, computer
clusters were not yet in wide use; instead, universities and
research institutes made heavy use of standalone super-
computers for demanding computations. The World
Wide Web was in its infancy and had not yet become es-
sential for day-to-day research.
The field would soon change dramatically. In the mid-
and late-1990s, the Internet revolutionized software de-
velopment and, along with it, computational genomics.
The rapid growth of the Internet catalyzed the Open
Source Software (OSS) and Free Software movements
[157], and the widespread adoption of Linux/GNU oper-
ating systems. These platforms, in turn, led to a major
shift in research computing away from proprietary Unix
systems and toward low-cost Linux systems running on
commodity hardware. Computer clusters built from in-
expensive components rapidly replaced high-end super-
computers (Fig. 1d). At the same time, the Internet
made it much easier, cheaper, and faster to ship software:
download buttons replaced telephone orders of floppy
disks or CDs. This easy and prolific dissemination of
code on the Internet fit well with the ethos of scientific
research, which tends to favor openness and shared re-
sources and to view profit-making with suspicion. Soon,
there was an explosion of free and open-source software
for genomics.
In my view, these trends were intensified by a gener-
ational shift in the research science community. By the
mid-1990s, the ranks of PhD students and young scien-
tists were swelling with a new cohort that had learned to
program computers as children, during the PC boom of
the 1980s. These young, computer-savvy researchers saw
little point in paying for software that they could write
themselves. In addition, many found a subversive excite-
ment in producing their own software and releasing the
code, free to anyone, on the emerging Internet. In this
brave new world, smart kids could go from an idea to a
working implementation to worldwide distribution
within days, with no need for investors, marketing
teams, or salespeople. Young scientists programmed
madly in research laboratories and coffee shops, often at
odd hours, communicating by email in a new ultra-
networked world, while some of their bosses still occu-
pied a musty world of paper journals, written letters,
and landline phones. This generational shift occurred
across all of science and engineering, but it was perhapsespecially pronounced in biology, where the previous
generation—except for a few influential pioneers—had
been generally slow to embrace computing technologies.
Whatever its cause, this creative and entrepreneurial
spirit helped to generate the rich landscape of free, aca-
demic software that we now enjoy in genomics. The “ar-
tisanal” model of software development in genomics also
has had the benefit of enabling rapid development of
new methods, a close coupling of software development
and research science, and a kind of esprit de corps
among bioinformatic tool developers around the world.
Nevertheless, some of the same features that have made
the field vibrant and productive have contributed to the
difficulty of progressing to a more rigorous and profes-
sional model of software development. In particular, the
surge of development over the past two decades, done in
large part by underpaid workers motivated by pure en-
thusiasm for their craft, has allowed the field to benefit
from a great deal of new software without being forced
to reckon with its true costs. Institutions have not been
forced to pay professional programmers competitive sal-
aries; grant agencies have not been compelled to set
aside appropriate funds for a software infrastructure;
and the line items for professional software engineering
have not made it into budget models. Thus, genomics
has become accustomed to, even addicted to, abundant
free software. In a sense, in our idealistic, anti-
establishment zeal, we free software warriors have locked
computational genomics into an unsustainable financial
model.Remedies: general principles
What, then, can be done to improve the financial and
development landscape for genomic software? I address
this question by first advancing some general principles,
and then putting forward some more specific implemen-
tation strategies.
First, a clearer recognition is needed—at all levels, ran-
ging from research institutions to granting agencies to
private companies—that software for genomic analysis is
a fundamental component of the infrastructure of gen-
omics and requires a substantial commitment of re-
sources. Software development is no less essential to
progress of the field, and no less complex and expensive
to carry out, than development of new genomic tech-
nologies or large-scale databases.
Second, commitments to the development of new soft-
ware must be accompanied by ongoing commitments to
the maintenance, refinement, and support of widely used
tools. Because some tools inevitably remain relevant and
widely used for longer than others, mechanisms will be
needed for determining which previously funded pro-
jects do and do not deserve ongoing support.
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be adapted to accommodate fundamental differences be-
tween software development projects and genomic re-
search projects. In particular, proposals for software
development projects should be evaluated in a way that
gives less weight to innovation and more weight to soft-
ware engineering practices, as well as to distribution,
maintenance, support, documentation, and usability.
Fourth, improved career paths are needed for software
developers working in academic research settings. Insti-
tutions and grant mechanisms must allow for salaries
that are competitive with industry, and better opportun-
ities for career advancement and continuing education.
Fifth, academic researchers and funding agencies must
remain open to the possibility that some aspects of soft-
ware development might be better done by private com-
panies and should consider ways to nurture the
development of sustainable business models based on
genomic software development.
Sixth, it would be a mistake to abandon the current
bottom-up model—with investigator-initiated software
development closely integrated with genomic research—in
favor of a top-down model, dominated by large, centrally
organized projects. Rather, a strategy is needed that em-
braces the strengths of our research-coupled model but
promotes software quality and financial sustainability.
Remedies: specific strategies
In keeping with the broad principles outlined above, I
propose specific strategies in three major areas: grant fund-
ing, career development, and commercial development.
Grant funding
There is clearly a need for continuing support for gen-
omic software development from government grants,
but the field would benefit substantially from improved
grant opportunities, review criteria, and budget models.
Some specific possibilities include:
▪ Changes to proposal formats and review criteria to
focus attention on the engineering aspects of software
projects that currently tend to be hidden in research
proposals. For example, proposals with substantial
software development components should be required
to address in detail how software will be tested,
distributed, and maintained, what user interfaces and
documentation will be provided, how version control
and bug-tracking will be managed, and how ongoing
support will be offered to users. Explicit review criteria
should be used to evaluate these features, and at least
one suitably trained reviewer should examine each
proposal with these criteria in mind.
▪ More government grant opportunities specifically
focused on software development, with review criteriaas described above. Review of these proposals should
also allow for a reduced emphasis on novelty or
innovation, as well as for the possibility that innovation
might occur at the software design or implementation
levels. A substantial fraction of these proposals should
be awarded to individual investigator-initiated software
projects, rather than being earmarked for large projects
or consortia. Perhaps the best example of this type of
funding in the US, at present, is the US National
Science Foundation (NSF) Infrastructure Capacity for
Biology program (formerly, Advances in Bioinformatics),
but the funds devoted to this program are modest
(Table 2), and they are spread across several types of
infrastructure, including facilities, equipment, and
biological collections.
▪ Many more government grant opportunities for the
maintenance, support, or refinement of existing, widely
used software tools. Programs of this kind were
previously available from the NIH (for example,
Continued Development and Maintenance of Software
and Extended Development, Hardening &
Dissemination of Technologies in Biomedical
Computing, Informatics, & Big Data Science; Table 2)
but have been discontinued. The new Investigator
Initiated Research in Computational Genomics and
Data Science program appears to be intended to
replace them, in part, but it has a broader scope, and it
is not clear how many awards will be funded through
it. An important issue to address here is how to
measure the impact and importance of existing
software tools—through citations, downloads, expert
opinion, or some other measure?
▪ Budget models that allow professional software
developers to be paid competitive salaries from
government grants. Current budgetary limits, such as
the typical $250,000 per year in direct costs for a
“modular” NIH grant, make it nearly impossible to pay
these workers appropriately and still have funds for
other necessities such as students, postdoctoral
researchers, supplies, and portions of principal
investigator salaries.
▪ Grant opportunities specifically designed to support
computational scientists who wish to continue
developing genomic software in a research setting, but
who do not wish to serve as independent investigators.
The US National Cancer Institute (NCI) Research
Specialist (R50) award could serve as a model for such
a program.
▪ More grant opportunities from private foundations
and companies to support genomic software
development. Private foundations, such as the W. M.
Keck, Alfred P. Sloan, and Simons Foundations and the
Wellcome Trust, have emerged as important auxiliary
sources of scientific funding, but their support for
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limited. Notable exceptions include the Data-Driven
Discovery program from the Gordon & Betty Moore
Foundation, the Collaborative Computational Tools for
the Human Cell Atlas program from the Chan-
Zuckerberg Initiative, and the Innovation in Cancer
Informatics fund (Table 2).
▪ More grant opportunities to support community
development for the kinds of distributed, open-source
projects that have been so successful in computational
genomics. For example, these grants could support
workshops, “hackathons”, competitions, and challenges
(such as CASP [158, 159] or DREAM [160]), creation
of standardized benchmarks for testing, and public
repositories for code and data.
Career development
As noted above, a crucial barrier to genomic software
development is the absence of stable and rewarding car-
eer paths for software developers working in academic
research settings. Some institutions have been more ef-
fective than others at promoting the careers of these in-
dividuals—notable examples include the European
Bioinformatics Institute, the Broad Institute, the UC
Santa Cruz Genomics Institute, and the New York Gen-
ome Center—but improvements are needed broadly
across the field. Aside from improved funding for salar-
ies (above), the following ideas could be considered:
▪ Improved job descriptions, salary scales, and paths for
career advancement, to allow recruitment and
retention of first-rate software developers despite
competition from industry. Software developers must
be provided with clear paths from entry-level positions
to jobs with increased pay, professional status, and/or
leadership potential. In addition, academic job categor-
ies and descriptions should avoid blurring the distinc-
tions among support roles; a software developer is not
the same as a laboratory technician, a data analyst, or a
systems administrator.
▪ Opportunities for continuing education. Software
developers work in a fast-moving field, with new
technologies continually emerging. They need to be
able to attend their own conferences, workshops, and
courses, just as researchers do. These activities would
improve their productivity, generate and maintain
excitement about their work, and help to create a sense
of parity with workers on the research track.
▪ Institutional recognition of the accomplishments of
software developers and other support staff. Some
academic institutions bestow a seemingly limitless
supply of awards and accolades on their faculty and
students, but the critically important efforts of
programmers, analysts, and technicians are too oftenoverlooked. Recognizing these individuals is a natural
way to help them feel valued.
▪ Encouragement for the development of forums for
intellectual exchange among software developers and
other staff members across an institution. For example,
in-house seminars could be organized to focus on new
programming languages, hardware resources, or other
technologies, or to showcase the technical underpinnings
of a new software release or data analysis.
Commercial development
A third major area concerns the development of a sus-
tainable commercial model to support aspects of soft-
ware development that may be more efficiently, and
more naturally, carried out in private companies than in
academic research environments. Ideas to consider
include:
▪ Grant mechanisms that make it easier to outsource
software development, maintenance, and support to
private companies, through contracts, consulting or
service fees, or other arrangements, instead of
implicitly encouraging academics to do this work for
themselves (often poorly). For grant proposals that
have a substantial software development component,
investigators should perhaps be explicitly asked to
present a rationale for their decision either to
outsource the work or do it in-house. Institutions and
granting agencies could facilitate outsourcing by
providing lists of companies with various types of
expertise.
▪ More proactive efforts by research institutions to spin
off companies that develop genomic software. Many
institutions have become much more active in
encouraging start-ups in recent years, but development
has been slow in the area of genomic software owing to
uncertainty about business models. Nevertheless, if
these efforts were paired with a push to outsource
some grant-funded activities, perhaps the business
models would begin to coalesce.
▪ More grants to support emerging genomic software
companies, through mechanisms such as the Small
Business Innovation Research (SBIR) program in the
US (which does indeed fund some current software
development activities).
▪ More efforts to expose graduate students and other
trainees to commercial opportunities, including
guidance on how to start their own companies, and
benefit from institutional incubators and small business
grants.
Conclusions
Genomic software is now a fundamental component of
the infrastructure for biological research. It is central to
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lions of dollars per year. Despite its crucial importance,
genomic software development is generally funded at
modest levels, primarily through a diffuse collection of
government grants to individual researchers in academic
research environments. This model is quite different
from those adopted for other aspects of the infrastruc-
ture for life sciences research, such as public databases,
which tend to be publicly funded but centrally orga-
nized, and laboratory equipment, which tends to be de-
veloped and marketed by private companies. The roots
of these differences lie in the rapid growth of genomic
software together with the emergence of the Internet, a
generational change in the adoption of computers in
biological research, and an affinity for the Open Source
movement of the 1990s. Despite important strengths,
the limitations of the current model are becoming in-
creasingly apparent, with unreliable and hard-to-use
software and inadequate maintenance and support,
resulting in wasted time and money.
I have argued here that we need major changes in the
way that we fund and carry out software development
for genomics. In general, I propose measures intended
to maintain the fundamental strengths of our current
investigator-driven, research-coupled model of software
development, but this model should be augmented with
improved engineering practices, funding opportunities,
career development, and commercial opportunities.
These proposed measures would require action at mul-
tiple levels including in individual research groups, in in-
stitutions, and at funding agencies. They would clearly
be costly. However, I believe that these costs are small in
comparison to the many hidden costs of failing to offer
a robust, reliable, efficient, and conveniently usable soft-
ware infrastructure for genomics—costs that will only
increase as the field grows in size and influence.
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